Search results (251)
« Back to NewsBioEscalator sponsors Oxford Catalyse Programme 2022
1 February 2022
The BioEscalator is sponsoring a prize for the Biohackaton 2022, where teams created during the Oxford Catalyse 2022 programme will pitch their final business plans to a panel of judges.
BioEscalator opens new laboratory
1 February 2022
In December 2021, the BioEscalator opened a brand-new 137m2 laboratory, providing much-needed additional incubator space for Oxford-based start-ups.
Introducing Alethiomics
1 February 2022
Alethiomics Ltd is a pre-clinical biotech company harnessing the power of single cell multiomic technology to discover and develop life-changing treatments for patients with blood cancer.
SIGA Announces Preclinical Oncology Research Collaboration with Bioarchitech
25 January 2022
The research collaboration will investigate TPOXX® (tecovirimat) in combination with Bioarchitech’s proprietary vaccinia-based immunotherapy platform in preclinical studies.
Kyttaro Announces an Exclusive Worldwide Licensing Agreement with Oxford University Innovation
3 January 2022
Kyttaro plans to develop a peptide technology platform to create novel biologic therapeutics addressing various causes of inflammation, a major mechanism underlying cardiovascular disease.
Ochre Bio Enters into Charitable Donation Agreement with British Liver Trust
14 December 2021
The two companies share the same goals, to improve the lives of those dealing with liver disease.
Exact Sciences Innovation graduates to The Oxford Science Park
22 November 2021
Helping people get the answers they need to make more informed decisions across the cancer continuum.
Introducing CyanoCapture
15 November 2021
CyanoCapture aims for scalable, low-cost, biological carbon capture using genetically-modified algae, known as cyanobacteria.
Gene Linked to Doubling the Risk of Death due to COVID-19 Identified Using Technology Exclusively Licensed to Nucleome Therapeutics
5 November 2021
The technology used to identify this gene has been exclusively licensed to Nucleome, highlighting the competitive advantage of Nucleome’s platform in the discovery of genetic targets for innovative precision medicine development.
Exogene selected for KQ Labs accelerator programme
4 November 2021
Exogene has been selected as one of ten innovative startup companies, working at the interface of biomedical and data science, to receive personalised mentoring and coaching as part of the KQ Labs accelerator programme.
Introducing Kyttaro
1 November 2021
Kyttaro is developing innovative therapeutics to treat hypertriglyceridemia, atherosclerotic cardiovascular disease and inflammatory and neurogastroenterology conditions.
Ochre Bio shortlisted as an OBN Awards 2021 finalist in the BioSeed ‘One to Watch’ Category
21 October 2021
Recipients of the OBN Awards are considered to have made an outstanding and valuable contribution to their field, which is why Ochre Bio is thrilled to have made the cut at this early stage of its life.
Oxford BioEscalator celebrates three years of innovation
31 August 2021
The BioEscalator concept was born out of a shared need by academic researchers and their bioscience company collaborators for start-up incubator space close to academic labs. The vision was to develop a leading international centre for innovative bioscience with the potential to make a significant impact on healthcare. The incubator provides spin-outs and start-ups with laboratory and business support, enabling them to grow into leading bioscience ventures.
BioEscalator companies attract record funding as investors switch-on to biotech
17 August 2021
Despite the disruption caused by the pandemic, BioEscalator companies attracted a record high of £1.2B investment. This is part of a trend that saw investors attracted to the resilience displayed by the life science industry to the pandemic relative to other sectors.
PepGen announces closing of $112.5M crossover financing to advance transformative therapies for neuromuscular diseases
4 August 2021
Proceeds to support expansion and advancement of PepGen’s pipeline of Enhanced Delivery Oligonucleotide (EDO) therapies for neuromuscular and neurologic diseases.
Theolytics graduates from the BioEscalator
22 July 2021
After a highly successful start, Theolytics is ready for the next step in its journey and is moving to The Oxford Science Park. The company will be the first tenant moving into the newly refurbished Sherard Building.
Introducing Oxford Silk Phage Technologies
4 July 2021
Oxford Silk Phage Technologies combines the long-term expertise of clinicians, entrepreneurs and scientists with a shared passion for developing superior, natural antibacterial biomaterials to help people live more active and longer lives.
Evolvere Biosciences joins the BioEscalator community after winning the OUBT Biohackathon 2021
4 July 2021
Evolvere joins our community for three months after winning the OUBT Biohacakthon 2021 BioEscalator sponsored prize.
MediMabBio establishes a bridgehead for the development of immuno-oncology drugs in the UK
24 June 2021
MediMabBio has started global clinical trials of its flagship pipeline. After securing R&D funding through a Series A round earlier this year, it will collaborate with a UK clinical trial institution to conduct joint research to develop a treatment for liver cancer.
Ochre Bio Raises $9.6M to Advance RNA Therapies for Liver Diseases
17 June 2021
The funding will be used to advance the development of Ochre Bio’s RNA therapies and expand its deep phenotyping platform to identify and validate new liver targets.